These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19746253)

  • 41. [Torsade de pointes induced by quinidine: a case treated successfully with verapamil].
    Ometto R; Arfiero S; Vincenzi M
    G Ital Cardiol; 1990 May; 20(5):431-4. PubMed ID: 2210166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relationship between early afterdepolarization and the occurrence of torsades de pointes--an in vivo canine model study.
    Sato T; Hirao K; Hiejima K
    Jpn Circ J; 1993 Jun; 57(6):543-52. PubMed ID: 8341001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
    Thomas SH; Behr ER
    Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Torsades de Pointes after Ondansetron Infusion in 2 Patients.
    Lee DY; Trinh T; Roy SK
    Tex Heart Inst J; 2017 Oct; 44(5):366-369. PubMed ID: 29259513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early afterdepolarizations, U waves, and torsades de pointes.
    Wu J; Wu J; Zipes DP
    Circulation; 2002 Feb; 105(6):675-6. PubMed ID: 11839619
    [No Abstract]   [Full Text] [Related]  

  • 46. Torsades de pointes from terfenadine and sotalol given in combination.
    Feroze H; Suri R; Silverman DI
    Pacing Clin Electrophysiol; 1996 Oct; 19(10):1519-21. PubMed ID: 8904547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Experimental models of torsades de pointes].
    Davy JM; Weissenburger J; Chezalviel F; Ertzbischoff O
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():15-21. PubMed ID: 1307190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts.
    Chiba K; Sugiyama A; Takasuna K; Hashimoto K
    Eur J Pharmacol; 2004 Oct; 502(1-2):117-22. PubMed ID: 15464097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
    Lu HR; Remeysen P; De Clerck F
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amiodarone and torsades de pointes in patients with advanced heart failure.
    Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
    Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes.
    Passman R; Kadish A
    Med Clin North Am; 2001 Mar; 85(2):321-41. PubMed ID: 11233951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe Torsades de Pointes with acquired QT prolongation.
    Narang A; Ozcan C
    Eur Heart J Acute Cardiovasc Care; 2019 Dec; 8(8):775-776. PubMed ID: 27154527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
    Sasse M; Paul T; Bergmann P; Kallfelz HC
    Pacing Clin Electrophysiol; 1998 May; 21(5):1164-6. PubMed ID: 9604253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
    Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
    J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cisapride-induced torsades de pointes.
    Vitola J; Vukanovic J; Roden DM
    J Cardiovasc Electrophysiol; 1998 Oct; 9(10):1109-13. PubMed ID: 9817562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Torsades de pointes after adenosine administration.
    Teodorovich N; Margolin E; Kogan Y; Paz O; Swissa M
    J Electrocardiol; 2016; 49(2):171-3. PubMed ID: 26850499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of methadone-induced torsades de pointes with lidocaine.
    Rajpal S; Mundi AS; Reddy PC; Akkus NI
    J La State Med Soc; 2013; 165(6):338-41. PubMed ID: 25073261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.